chronic kidney dz management in HIV guidelines


An updated guideline came out of the Infectious Diseases Society of America on the management of chronic kidney disease in patients with HIV (see hiv chr kidney dz infect dis society 2014 in dropbox, or doi:10.1093/cid/ciu730​). they note that chronic kidney disease is common in people with HIV, can be multifactorial (including direct HIV renal involvement and adverse medication effects), and is itself associated with increased morbidity and mortality. people with HIV with decreased GFR and albuminuria have an even higher risk of cardiovascular events (6-fold) than the increased risk in the general population (of note, the decreased GFR and albuminuria are independently associated with cardiovascular events, worse if both are present). 

the guideline committee stresses that these are guidelines and not intended to supplant clinical judgment in the management of individual patients. recommendations:

--check eGFR when antiretroviral therapy is initiated or changed, and at least twice a year in stable patients (strong rec, low qual evidence)
--check urine with urinalysis or quantitative measure of albuminuria/proteinuria at baseline, when HIV meds initiated or changed, and at least annually (weak rec, low qual evidence)
--in those with new-onset/newly discovered kidney disease, check chem panel, urinalysis, quantitative albuminuria (eg albumin/creat ratio from spot urine), assess temporal trends in eGFR, blood pressure, glucose in diabetics, markers of proximal tubular dysfunction (eg increased excretion of phosphorus and glycosuria with normal blood sugar are both highly specific markers of proximal tubular dysfunction) esp in those on tenofovir, renal ultrasound, review meds including nonprescription ones for both potential cause of renal dysfunction and if renal dosing required  (strong rec, low qual evidence) [some studies have also found increased tenofovir nephrotoxicity when combined with atazanavir, amprenavir or ritonavir-boosted PIs]
--their table 6 reviews the different HIV meds and renal dose-adjustments for decreased GFR [this is really helpful]
--refer to nephrologist if clinically significant decline in GFR (eg >25%, or if <60 ml/min/1.73m2). also consider if albuminuria>300mg/d or hematuria of renal origin. HIVAN (HIV associated nephropathy) typically presents with massive proteinuria in setting of advanced HIV disease, but one can be fooled, and biopsy is reasonable if considering steroid therapy.
--use either CKD Epidemiology Collaboration (CKD-EPI) to estimate GFR or Cockcroft-Gault equation to estimate creatinine clearance (strong rec, moderate qual evidence) -- both of these need just serum creatinine, age, gender. CKD-EPI more accurate, esp if GFR>60. for calculators, go to https://www.kidney.org/professionals/ 
--avoid tenofovir or other nephrotoxins (eg NSAIDS) if GFR<60 (strong rec, low qual evidence). also avoid in prepubertal children because of renal effects and bone mineral density loss
--if already on tenofovir and GFR declines >25% and to level<60, substitute alternative med (strong rec, low qual evidence)
--use ACE-I or ARB in people with HIVAN or clinically significant albuminuria (>30mg/d in diabetics, >300mg/d in nondiabetics(strong rec, high qual evidence)
--use statins if high risk of cardiovasc disease (strong rec, high qual evidence), aspirin balanced against individual's bleeding risk (weak rec, high qual evidence)
--BP targets are <140/90 in those with CKD and albuminuria <30gm/d (strong rec, moderate qual evidence); <130/80 if albuminuria 30-300 mg/d (weak rec, low qual evidence) [note that these differ from JNC-8 targets]
--consider steroids as adjunct to ART and ACE-I/ARB if biopsy confirmed HIVAN (weak rec, low qual evidence)​, though not in children
--in patients with ESRD, consider transplant (rates of patient/graft survival are now pretty high).

so, i think pretty useful guidelines, esp some of their tables (eg table 6 as noted, for renal dosing of HIV meds. other tables deal with antibiotic dosing and drug-drug interactions for immunosuppressants and HIV drugs -- eg prednisone, tacrolimus...)


Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more